InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

Current share price for CU6 : $2.190 0.04 (1.86%)+

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$815 Corporate Presentation - Wilsons Drug and Device Conference 28 Oct 2022 1:23PM $0.640 $2.185 risen by 241.41%
$815 50% recruitment milestone reached for prostate cancer trial 27 Oct 2022 9:49AM $0.610 $2.185 risen by 258.20%
$815 Notice of Annual General Meeting/Proxy Form 25 Oct 2022 9:58AM $0.595 $2.185 risen by 267.23%
$815 Application for quotation of securities - CU6 13 Oct 2022 3:14PM $0.600 $2.185 risen by 264.17%
$815 Notification of cessation of securities - CU6 12 Oct 2022 12:39PM $0.615 $2.185 risen by 255.28%
$815 First patient treated in therapeutic prostate cancer trial 7 Oct 2022 9:46AM $0.615 $2.185 risen by 255.28%
$815 First participant imaged in Phase II SAR-Bombesin trial 6 Oct 2022 9:58AM $0.625 $2.185 risen by 249.60%
$815 Date of AGM 30 Sep 2022 4:35PM $0.640 $2.185 risen by 241.41%
$815 Corporate Governance Annual Statement 15 Sep 2022 10:01AM $0.630 $2.185 risen by 246.83%
$815 Annual Report to shareholders 15 Sep 2022 10:00AM $0.630 $2.185 risen by 246.83%
$815 First participants imaged in SAR-Bombesin trial 14 Sep 2022 9:31AM $0.640 $2.185 risen by 241.41%
$815 Radiopharmaceuticals Expert Joins Clarity as Chief Scientifi 13 Sep 2022 9:50AM $0.655 $2.185 risen by 233.59%
$815 Clarity strengthens protection of the SAR-bisPSMA product 12 Sep 2022 1:36PM $0.640 $2.185 risen by 241.41%
$815 Recruitment opens for Phase II trial in Prostate Cancer 5 Sep 2022 8:56AM $0.635 $2.185 risen by 244.09%
$815 Preliminary Final Report 24 Aug 2022 1:05PM $0.725 $2.185 risen by 201.38%
$815 Paediatric neuroblastoma trial advances to cohort 3 23 Aug 2022 9:53AM $0.700 $2.185 risen by 212.14%
$815 Imaging trial in prostate cancer opens for recruitment 22 Aug 2022 10:01AM $0.635 $2.185 risen by 244.09%
$815 Notification regarding unquoted securities - CU6 16 Aug 2022 12:05PM $0.640 $2.185 risen by 241.41%
$815 Clarity expands manufacturing capabilities 11 Aug 2022 9:45AM $0.615 $2.185 risen by 255.28%
$815 Clarity and Evergreen expand TCT manufacturing 9 Aug 2022 10:01AM $0.580 $2.185 risen by 276.72%
$815 Quarterly Activities/Appendix 4C Cash Flow Report 27 Jul 2022 10:43AM $0.620 $2.185 risen by 252.42%
$815 Recruitment complete for diagnostic prostate cancer trial 20 Jul 2022 9:35AM $0.610 $2.185 risen by 258.20%
$815 Notification of cessation of securities - CU6 7 Jul 2022 3:59PM $0.510 $2.185 risen by 328.43%
$815 Change of Director's Interest Notice - Biggin 6 Jul 2022 4:49PM $0.500 $2.185 risen by 337%
$815 Notification regarding unquoted securities - CU6 6 Jul 2022 3:54PM $0.515 $2.185 risen by 324.27%

401 - 425 of 512 results

Page 17 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.